|
Belgium Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The Belgium Pharmaceuticals and Healthcare Report
Independent 5-year pharmaceutical and healthcare industry forecasts for Belgium.
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Belgian pharmaceutical and healthcare industry.
Competitive intelligence, Belgian pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Belgian market.
The Belgium Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’s Belgium Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Belgian pharmaceutical and healthcare industry.
Key Benefits of Report
- Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Belgium to test other views – a key input for successful budgeting and strategic business planning in the Belgian pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the Belgian Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Belgium.
- Exploit The Latest Competitive Belgian Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Belgium.
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
- Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
- Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
- OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
- Generics market (US$bn)/ as % of total market
- Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
|
Belgium Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Chapter - Executive Summary |
| Belgium Pharmaceuticals And Healthcare Industry SWOT |
| Belgium Political SWOT |
| Belgium Economic SWOT |
Chapter - Pharmaceutical Business Environment Ratings |
| Table: Western Europe Pharmaceutical Business Environment Ratings |
| Limits Of Potential Returns |
Chapter - Belgium – Market Summary |
| Regulatory Regime |
| Intellectual Property Environment |
| Pricing And Reimbursement Regime |
| Pricing And Reimbursement Developments |
Chapter - Industry Developments |
| Healthcare Sector |
| Recent Healthcare Sector Developments |
| Epidemiology |
| Table: Disease Burden In Western Europe |
| Generics Sector |
| Research And Development Sector |
Chapter - Industry Forecast Scenario |
| Overall Market Forecast |
| Table: Belgium's Drug Market Indicators, 2004-2013 |
| Key Growth Factors – Industry |
| Table: Belgium's Health Expenditure Indicators, 2004-2013 |
| Key Growth Factors – Macroeconomic |
| Table: Belgium - Economic Activity |
| Prescription Market Forecast |
| Table: ATC Breakdown Prescription Drug Market US$mn |
| Patented Market Forecast |
| Table: Belgium's Patented Drugs Market Indicators, 2004-2013 |
| OTC Market Forecast |
| Table: Belgium's OTC Drugs Market Indicators, 2004-2013 (US$mn unless otherwise stated) |
| Generics Market Forecast |
| Table: Belgium's Generics Drug Market Indicators, 2004-2013 |
| Export/Import Forecasts |
| Table: Belgium's Pharmaceuticals Exports And Imports, 2004-2013 (US$mn) |
| Other Healthcare Data Forecasts |
| Table: Belgium's Healthcare Data Indicators, 2005-2012 |
| Key Risks To BMI's Forecasts |
Chapter - Competitive Landscape |
| Recent Company Developments |
Chapter - Company Monitor |
| Leading Multinational Manufacturers |
| GlaxoSmithKline (GSK) |
| Pfizer |
| Novartis |
| Sanofi-Aventis |
| Merck & Co |
| Leading Indigenous Manufacturers |
| UCB Pharma |
| Solvay |
| Janssen Pharmaceutica |
| Omega Pharma |
Chapter - Country Snapshot: Belgium Demographic Data |
| Section 1: Population |
| Table: Demographic Indicators, 2005-2030 |
| Table: Rural/Urban Breakdown, 2005-2030 |
| Section 2: Education And Healthcare |
| Table: Education, 2002-2005 |
| Table: Vital Statistics, 2005-2030 |
| Section 3: Labour Market And Spending Power |
| Table: Employment Indicators, 2001-2006 |
| Table: Consumer Expenditure, 2000-2012 (US$) |
| Table: Average Annual Wages, 2000-2012 |
Chapter - BMI Forecast Modelling |
| How We Generate Our Pharmaceutical Industry Forecasts |
| Pharmaceutical Business Environment Ratings Methodology |
| Ratings Overview |
| Table: Pharmaceutical Business Environment Indicators |
| Weighting |
| Table: Weighting Of Components |
| Sources |
|
Belgium Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
BMI calculates Belgium’s pharmaceutical expenditure to have been EUR4.08bn (US$5.61bn) in 2008. By 2013, we expect the total amount spent on prescription and over-the-counter (OTC) medicines to have reached a value of EUR4.42bn equating to a compound annual growth rate (CAGR) of 1.8%. In US dollar terms, however, as a result of the weakening Euro, drug market expenditure will fall from US$5.61bn in 2009 to US$5.59bn in 2013.
In BMI’s all new Business Environment Rankings for Q209, Belgium has moved up to 3rd place in the Western Europe region. The Belgian pharmaceuticals market is among the top 5 in Western Europe and globally, Belgium is ranked in 5th position just behind Switzerland and Japan, after moving up 7 places in Q209.
Belgium has a relatively high per capita drug expenditure rate, at an estimated US$526 in 2008. However, a relatively stable population and rising social security expenditure have led the government to undertake severe measures to reduce expenditure on healthcare in general, and on pharmaceuticals in particular.
However, studies show that patients in Belgium pay significantly more for their medicines than those in other select European countries. A study carried out by the Belgian organisation Platform for Action for Health and Solidarity indicated that on average patients in Belgium pay 50% more for their medicines than patients in the Netherlands. For example, the most commonly prescribed drug for reducing cholesterol, Zocor (simvastatin), is five to seven times more expensive in Belgium than in the Netherlands. The most commonly prescribed drug to counteract stomach acid, Losec (omeprazole), is nine to 17 times more expensive in Belgium than in the Netherlands.
New regulations that came into effect in February 2009 allow patients in Belgium to buy non-prescription medicines online. Georges Gilinket, an MP for the Belgian political party Ecolo said that his party was very critical of the legislation as ‘taking medicines should not be trivialised and nothing should replace direct contact between a patient and their pharmacist’. There was also a concern that the development will encourage self-medication. Additionally, Belgium’s drugs agency – L’Agence Fédérale des Médicaments et des Produits de Santé (AFMPS) –expressed its concerns regarding health risks that may evolve as a result of patients purchasing medicines online via illegal networks.
|
Belgium Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Africa |
| Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe |
Asia |
| Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam |
Caribbean |
| Puerto Rico |
Europe |
| Belarus, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan |
Latin America |
| Argentina, Brazil, Chile, Colombia, Mexico, Peru and Venezuela |
Middle East |
| Bahrain, Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates |
North America |
| Canada and United States |
Business Monitor InternationalA Market Leader in Country Risk, Industry Intelligence and Company Research Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK |
BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world. Country Risk Analysis and Forecasts Industry Intelligence and Market Research Company Research |